--- title: "ISpecimen Rallies On Biospecimen Marketplace Expansion" type: "News" locale: "en" url: "https://longbridge.com/en/news/278997644.md" description: "Shares of iSpecimen Inc. (ISPC) surged 62% to $0.36 after the launch of its AI-powered Inventory Agent, aimed at modernizing biospecimen procurement. This tool utilizes large language models to efficiently match specimen requests with available inventory while maintaining expert oversight for quality. CEO Katie Field highlighted the launch as a significant milestone, enhancing access to critical samples for researchers. iSpecimen plans to further expand its AI capabilities, including regulatory monitoring and workflow automation. The stock has fluctuated between $0.22 and $3.18 over the past year, closing at $0.22 before the surge." datetime: "2026-03-13T07:10:32.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278997644.md) - [en](https://longbridge.com/en/news/278997644.md) - [zh-HK](https://longbridge.com/zh-HK/news/278997644.md) --- # ISpecimen Rallies On Biospecimen Marketplace Expansion (RTTNews) - Shares of iSpecimen Inc., (ISPC) were up 62% at $0.36 in the overnight session, following news of the company launching its new AI-powered Inventory Agent. The AI-powered Inventory Agent is designed to streamline how specimen requests are matched with available inventory across iSpecimen's global supplier network, marking a step forward in modernizing biospecimen procurement. The agent uses large language models (LLMs) to analyze incoming requests, extract key criteria such as disease conditions and sample types, and identify potential matches with greater speed and accuracy. The company emphasized that while the AI system automates the initial review process, expert oversight remains central to ensuring quality and compliance. The tool is embedded within iSpecimen's redesigned marketplace platform, offering researchers a conversational interface to submit requests in plain language. Chief Executive Officer Katie Field described the launch as a milestone in iSpecimen's mission to optimize biospecimen sourcing. She noted that the technology is expected to enhance outcomes for suppliers, customers, and researchers by reducing friction and accelerating access to critical samples. Looking ahead, iSpecimen plans to expand its AI capabilities further, including features for regulatory monitoring, workflow automation, and intelligent outreach management. These initiatives reflect the company's broader commitment to modernizing the biospecimen procurement process and supporting the evolving needs of the research community. ISPC has traded between $0.22 and $3.18 over the past year. The stock closed Thursday's trading session at $0.22, down 6.67%. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [ISPC.US](https://longbridge.com/en/quote/ISPC.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [IDNA.US](https://longbridge.com/en/quote/IDNA.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Natera: Premium-Valued Leader in MRD Positioned for Long-Term Growth and Margin Expansion](https://longbridge.com/en/news/282586000.md) - [Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst](https://longbridge.com/en/news/282733296.md) - [Aligos expands Phase 2 B-SUPREME HBeAg- cohort for pevifoscorvir sodium HBV trial](https://longbridge.com/en/news/282738920.md) - [Ocumetics attends ASCRS annual meeting, reports productive talks with ophthalmic leaders](https://longbridge.com/en/news/282732136.md) - [Revolution Medicines' experimental cancer pill helps improve survival in late-stage study](https://longbridge.com/en/news/282540793.md)